Dr. Reddy's Laboratories · NSE: DRREDDY · BSE: 500124

Q1 FY23 results · Apr–Jun 2022

Dr. Reddy's Laboratories reported revenue from operations of ₹5,232.90 crore (up 5.8% from Q1 FY22) and net profit of ₹1,189.00 crore (up 212.6% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY23	Q1 FY22	YoY	Q4 FY22	QoQ
Revenue from operations	5,232.90	4,945.10	+5.8%	5,474.90	−4.4%
Other income	853.90	107.90	+691.4%	121.90	+600.5%
Total income	6,086.80	5,053.00	+20.5%	5,596.80	+8.8%
Profit before share of associates & JVs and tax	1,458.60	539.20	+170.5%	248.40	+487.2%
Share of profit/(loss) of associates & JVs	9.40	16.60		10.50
Net profit for the period	1,189.00	380.40	+212.6%	97.00	12x
EPS, basic (₹)	71.64	22.95	+212.2%	5.84	12x
Net margin (%)	22.7	7.7		1.8

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY23	Q1 FY22	YoY	Q4 FY22	QoQ
Revenue from operations	3,630.60	3,433.50	+5.7%	3,668.70	−1.0%
Other income	403.40	186.20	+116.6%	114.70	+251.7%
Total income	4,034.00	3,619.70	+11.4%	3,783.40	+6.6%
Profit before tax	751.60	544.50	+38.0%	566.70	+32.6%
Net profit for the period	499.50	413.40	+20.8%	419.70	+19.0%
EPS, basic (₹)	30.10	24.94	+20.7%	25.29	+19.0%
Net margin (%)	13.8	12.0		11.4

Consolidated

Filed with BSE: 29 Jul 2022, 10:49 IST
Board meeting: 28 Jul 2022
Period: 01 Apr 2022 to 30 Jun 2022
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 29 Jul 2022, 10:49 IST
Board meeting: 28 Jul 2022
Period: 01 Apr 2022 to 30 Jun 2022
Review status: Unaudited
Source: XBRL filing on BSE